The next COVID vaccines should exclude the original strain of SARS-CoV-2 and exclusively target the Omicron XBB subvariants, according to FDA staff members.
They unveiled their recommendation in a briefing document ahead of Thursday’s meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), stating that “the totality of available evidence suggests that a monovalent XBB-lineage vaccine is warranted for the 2023-2024 vaccination campaign.”
XBB strains are more immune evasive than prior Omicron subvariants and currently account for about 95% of COVID-19 cases worldwide, the agency staffers noted.
In the U.S., eight XBB strains account for over 98% of the current cases, according to CDC’s Nowcast tracker, including three sublineages under consideration for the fall vaccine: XBB.1.5 in 40%, and the newer XBB.1.16 in 18% and XBB.2.3 in 6% of cases.
Spike proteins of these three sublineages “are similar with few amino acid differences … and available studies suggest little to no further immune evasion from these new substitutions in the XBB.1.16 spike compared to XBB.1.5,” noted FDA staff.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.